Skip to main content
SpringerLink
Log in

Thyroid

  • Chapter
Surgery

Abstract

The common indications for thyroidectomy include a suspicion of cancer, local symptoms of a large neck mass (e.g., difficulty breathing or swallowing), and abnormal thyroid function (e.g., hyperthyroidism). Surgical management of thyroid problems requires a thorough understanding of the anatomy and pathophysiology of the thyroid gland.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am 1995; 79: 169–184.

    CAS  Google Scholar 

  2. Yoshida D. Thyroid storm precipitated by trauma. J Emerg Med 1996; 14: 697–701.

    PubMed  CAS  Google Scholar 

  3. Brown RS. Editorial: Immunoglobulins affecting thyroid growth: a continuing controversy. J Clin Endocrinol Metab 1996; 80: 1506–1508.

    Google Scholar 

  4. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103: 958–962.

    PubMed  CAS  Google Scholar 

  5. Razack MS, Lore JM, Lippes HA, Schaefer DP, Rassael H. Total thyroidectomy for Graves’ disease. Head Neck 1997; 19: 378–383.

    PubMed  CAS  Google Scholar 

  6. Linos DA, Karakitsos D, Pappademetriou J. Should the primary treatment of hyperthyroidism be surgical? Eur J Surg 1997; 163: 651–657.

    PubMed  CAS  Google Scholar 

  7. Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990; 70: 830–835.

    PubMed  CAS  Google Scholar 

  8. Joseph UA, Jhingran SG. Graves’ disease and concurrent thyroid carcinoma: the importance of thyroid scintigraphy in Graves’ disease. Clin Nucl Med 1995; 20: 416–418.

    PubMed  CAS  Google Scholar 

  9. Levy EG. Treatment of Graves’ disease: the American way. Bail-here’s Clin Endocrinol Metab 1997; 11: 585–595.

    CAS  Google Scholar 

  10. Witte J, Goretzki PE, Roher HD. Surgery for Graves disease in childhood and adolescence. Exp Clin Endocrinol Diabetes 1997; 105: 58–60.

    PubMed  CAS  Google Scholar 

  11. Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery (St. Louis) 1996; 11: 1020–1025.

    Google Scholar 

  12. Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. J Clin Endocrinol Metab 1996; 81: 2986–2993.

    PubMed  CAS  Google Scholar 

  13. Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996; 134: 710–215.

    PubMed  CAS  Google Scholar 

  14. Sugino K, Mimura T, Ozaki O, et al. Management of recurrent hyperthyroidism in patients with Graves’ disease treated by subtotal thyroidectomy. J Endocrinol Invest 1995; 18: 415–419.

    PubMed  CAS  Google Scholar 

  15. Abe Y, Sato H, Noguchi M, et al. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves’ disease. World J Surg 1998; 22: 714–717.

    PubMed  CAS  Google Scholar 

  16. Siegel RD, Lee SL. Toxic nodular goiter. Endocrinol Metab Clin North Am 1998; 27: 151–168.

    PubMed  CAS  Google Scholar 

  17. Erickson D, Gharib H, Li H, vanHeerden JA. Treatment of patients with toxic multinodular goiter. Thyroid 1998; 8: 277–282.

    PubMed  CAS  Google Scholar 

  18. David E, Rosen IB, Bain J, James J, Kirsh JC. Management of the hot thyroid nodule. Am J Surg 1995; 170: 481–483.

    PubMed  CAS  Google Scholar 

  19. Rojdmark J, Jarhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre. Eur J Surg 1995; 161: 725727.

    Google Scholar 

  20. Seiler CA, Glaser C, Wagner HE. Thyroid gland surgery in an endemic region. World J Surg 1996; 20: 593–597.

    PubMed  CAS  Google Scholar 

  21. Mack E. Management of patients with substernal goiters. En-doer Surg 1995; 75: 377–394.

    CAS  Google Scholar 

  22. Newman E, Shaha AR. Substernal goiter. J Surg Oncol 1995; 60: 207–212.

    PubMed  CAS  Google Scholar 

  23. Allo MD, Thompson NW. Rationale for the operative management of substernal goiters. Surgery (St. Louis) 1983; 94: 969–977.

    CAS  Google Scholar 

  24. Torre G, Borgonovo G, Amato A, et al. Surgical management of substernal goiter: analysis of 237 patients. Am Surg 1995; 61: 826–831.

    PubMed  CAS  Google Scholar 

  25. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553–559.

    PubMed  CAS  Google Scholar 

  26. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 156: 2165–2172.

    PubMed  CAS  Google Scholar 

  27. Sabel MS, Staren ED, Gianakakis LM, Dwarakanathan S, Prinz RA. Effectiveness of the thyroid scan in evaluation of the solitary thyroid nodule. Am Surg 1997; 63: 660–664.

    PubMed  CAS  Google Scholar 

  28. Agrawal S. Diagnostic accuracy and role of fine needle aspiration cytology in management of thyroid nodules. J Surg Oncol 1995; 58: 168–172.

    PubMed  CAS  Google Scholar 

  29. Woeber KA. Cost-effective evaluation of the patient with a thyroid nodule. Endocr Surg 1995; 75: 357–363.

    CAS  Google Scholar 

  30. Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 1998; 8: 283–289.

    PubMed  CAS  Google Scholar 

  31. Rodriquez JM, Parrilla P, Sola S, et al. Comparison between preoperative cytology and intraoperative frozen-section biopsy in the diagnosis of thyroid nodules. Br J Surg 1994; 81: 1151–1154.

    Google Scholar 

  32. Chen H, Zeiger MA, Clark DP, Westra WH, Udelsman R. Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration? J Am Coll Surg 1997; 184: 605–610.

    PubMed  CAS  Google Scholar 

  33. Aguilar-Diosdado M, Contreras A, Gavilan I, et al. Thyroid nodules: role of fine needle aspiration and intraoperative frozen section examination. Acta Cytol 1997; 41: 677–682.

    PubMed  CAS  Google Scholar 

  34. Chen H, Nicol TL, Udelsman R. Follicular lesions of the thyroid: does frozen section evaluation alter operative management? Ann Surg 1995; 222: 101–106.

    PubMed  CAS  Google Scholar 

  35. McHenry CR, Raeburn C, Strickland T, Marty JJ. The utility of routine frozen section examination for intraoperative diagnosis of thyroid cancer. Am J Surg 1996; 172: 658–661.

    PubMed  CAS  Google Scholar 

  36. Hamming JF, Vriens MR, Goslings BM, Songun I, Fleuren GJ, VanDeVelde CJH. Role of fine-needle aspiration biopsy and frozen section examination in determining the extent of thyroidectomy. World J Surg 1998; 22: 575–580.

    PubMed  CAS  Google Scholar 

  37. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery (St. Louis) 1994; 116: 1054–1060.

    CAS  Google Scholar 

  38. Chen H, Nicol TL, Zeiger MA, et al. Hurthle cell neoplasms of the thyroid. Ann Surg 1998; 227: 542–546.

    PubMed  CAS  Google Scholar 

  39. Paphavasit A, Thompson GB, Hay ID, et al. Follicular and Hurthle cell thyroid neoplasms. Arch Surg 1997; 132: 674–679.

    PubMed  CAS  Google Scholar 

  40. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA-Cancer J Clin 1998; 48: 6–30.

    PubMed  CAS  Google Scholar 

  41. Doniach I. Carcinogenic effect of 100, 250 and 500 rad x-rays on the rat thyroid gland. Br J Cancer 1974; 30: 487–495.

    Google Scholar 

  42. Fraker DL. Radiation exposure and other factors that predispose to human thyroid neoplasia. Endocr Surg 1995; 75: 365–375.

    CAS  Google Scholar 

  43. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. New Engl J Med 1991; 325: 599–605.

    PubMed  CAS  Google Scholar 

  44. Shore RE, Hildreth N, Dvoretsky P, Andresen E, Moseson M, Pasternack B. Thyroid cancer among persons given x-ray treatment in infancy for an enlarged thymus gland. Am J Epidemiol 1993; 137: 1068–1080.

    PubMed  CAS  Google Scholar 

  45. Ron E, Modan B, Preston D, et al. Thyroid neoplasias following low-dose radiation in childhood. Radiat Res 1989; 120: 516–531.

    PubMed  CAS  Google Scholar 

  46. Nagataki S, Shibata Y, Inoue S, Yokoyama N, Izumi M, Shimaoka K. Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA l994; 272: 384–370.

    Google Scholar 

  47. Doniach I. Experimental induction of tumours of the thyroid by radiation. Br Med J 1958; 14: 181–183.

    CAS  Google Scholar 

  48. McDougall LR, ed. Thyroid Disease in Clinical Practice. London: Chapman & Hall, 1992: 304–324.

    Google Scholar 

  49. Tezelman S, Grossman RF, Siperstein AE, Clark OH. Radioiodine-associated thyroid cancers. World J Surg 1994; 18: 522–528.

    PubMed  CAS  Google Scholar 

  50. Holm L-E, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83: 1072–1077.

    PubMed  CAS  Google Scholar 

  51. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974; 38: 976–998.

    PubMed  CAS  Google Scholar 

  52. Smith WG, Kern BB. The nature of the mutation in familial multiple polyposis: papillary carcinoma of the thyroid, brain tumors, and familial multiple polyposis. Dis Colon Rectum 1973; 16: 264–271.

    PubMed  CAS  Google Scholar 

  53. Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 1994; 79: 1317–1321.

    PubMed  CAS  Google Scholar 

  54. Grossman RF, Tu S-H, Duh Q-Y, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. Arch Surg 1995; 130: 892–897.

    PubMed  CAS  Google Scholar 

  55. Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (Loud) 1993; 363: 458–460.

    CAS  Google Scholar 

  56. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851–856.

    PubMed  CAS  Google Scholar 

  57. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994; 3: 237–241.

    PubMed  CAS  Google Scholar 

  58. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype of MEN 2A and FMTC. Nat Genet 1994; 6: 70–74.

    PubMed  CAS  Google Scholar 

  59. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89: 1517–1522.

    PubMed  CAS  Google Scholar 

  60. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D1OS170 and RET and creating the oncogenic sequence RETI PET. Med Sci 1992; 89: 1616–1620.

    CAS  Google Scholar 

  61. Tong Q, Li Y, Smanik PA, Fithian LJ, Xing S, Mazzaferri EL, Jhiang SM. Characterization of the promoter region and oligomerization domain of H4 (D105170), a gene frequently rearranged with the ret proto-oncogene. Oncogene 1995; 10: 1781–1787.

    PubMed  CAS  Google Scholar 

  62. Sozzi G, Bongarzone I, Miozzo M, et al. A t(10;17) translocation creates the RETJPTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 1994; 9: 244–250.

    PubMed  CAS  Google Scholar 

  63. Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994; 54: 2979–2985.

    PubMed  CAS  Google Scholar 

  64. Teyssier J-R, Liautaud-Roger F, Ferre D, Patey M, Dufer J. Chromosomal changes in thyroid tumors: relation with DNA content, karyotypic features, and clinical data. Cancer Genet Cytogenet 1990; 50: 249–263.

    PubMed  CAS  Google Scholar 

  65. Belge G, Thode B, Bullerdiek J, Bartnitzke S. Aberrations of chromosome 19. Cancer Genet Cytogenet 1992; 60: 23–26.

    PubMed  CAS  Google Scholar 

  66. DalCin P, Sneyers W, Aly MS, et al. Involvement of 19813 in follicular thyroid adenoma. Cancer Genet Cytogenet 1992; 60: 99–101.

    CAS  Google Scholar 

  67. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. En-doer Rev 1994; 15: 202–232.

    CAS  Google Scholar 

  68. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-Ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery (St. Louis) 1994; 116: 1010–1016.

    CAS  Google Scholar 

  69. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4: 1474–1479.

    PubMed  CAS  Google Scholar 

  70. Simon D, Goretzki PE, Gorelev V, et al. Significance of p53 in human thyroid tumors. World J Surg 1994; 18: 535–541.

    PubMed  CAS  Google Scholar 

  71. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 1994; 47: 337–339.

    PubMed  CAS  Google Scholar 

  72. Nishida T, Nakao K, Hamaji M, Nakahara M-A, Tsujimoto M. Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery (St. Louis) 1996; 119: 568–575.

    CAS  Google Scholar 

  73. Grebe SKG, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995; 24: 761–801.

    PubMed  CAS  Google Scholar 

  74. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. Cancer (Phila) 1993; 71: 4022–4029.

    CAS  Google Scholar 

  75. Allo MD, Christianson W, Koivunen D. Not all “occult” papillary carcinomas are “minimal.” Surgery (St. Louis) 1988; 104: 971–976.

    CAS  Google Scholar 

  76. Patwardhan N, Cataldo T, Braverman LE. Surgical management of the patient with papillary cancer. Surg Clin North Am 1995; 75: 449–464.

    PubMed  CAS  Google Scholar 

  77. Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 1996; 25: 115–139.

    PubMed  CAS  Google Scholar 

  78. Wong JB, Kaplan MM, Meyer K, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19: 741–760.

    PubMed  CAS  Google Scholar 

  79. Stephenson BM, Wheeler MH, Clark OH. The role of total thyroidectomy in the management of differentiated thyroid cancer. Curr Opin Gen Surg 1994; 53–59.

    Google Scholar 

  80. Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992; 16: 547–554.

    PubMed  CAS  Google Scholar 

  81. Hoelting T, Buhr HJ, Herfarth C. Intraoperative tumour classification in papillary thyroid cancer-a diagnostic dilemma. Eur J Surg Oncol 1995; 21: 353–356.

    PubMed  CAS  Google Scholar 

  82. Liu Q, Djuricin G, Prinz RA. Total thyroidectomy for benign thyroid disease. Surgery (St Louis) 1998; 123: 2–7.

    CAS  Google Scholar 

  83. Burge MR, Zeise T-M, Johnsen MW, Conway MJ, Qualls CR. Risks of complication following thyroidectomy. J Gen Intern Med 1998; 13: 24–31.

    PubMed  CAS  Google Scholar 

  84. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery (St. Louis) 1988; 104: 947–953.

    CAS  Google Scholar 

  85. Nguyen KV, Dilawari RA. Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am Surg 1995; 61: 151–155.

    PubMed  Google Scholar 

  86. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997; 4: 328–333.

    PubMed  CAS  Google Scholar 

  87. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1988; 133: 419–425.

    Google Scholar 

  88. Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 1998; 227: 912–921.

    PubMed  CAS  Google Scholar 

  89. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural his-tory, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414–424.

    Google Scholar 

  90. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714–720.

    PubMed  CAS  Google Scholar 

  91. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428.

    PubMed  CAS  Google Scholar 

  92. Loh K-C, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553–3562.

    PubMed  CAS  Google Scholar 

  93. Weigel RJ. Advances in the diagnosis and management of well-differentiated thyroid cancers. Curr Opin Oncol 1996; 8: 37–43.

    PubMed  CAS  Google Scholar 

  94. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7: 277–280.

    PubMed  CAS  Google Scholar 

  95. McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e., it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18: 505–512.

    PubMed  CAS  Google Scholar 

  96. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488–1492.

    PubMed  CAS  Google Scholar 

  97. McDougall IR 131I treatment of 1311 negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997;7:669–672.

    Google Scholar 

  98. Arad E, O’Mara RE, Wilson GA. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma. Clin Nucl Med 1993; 18: 662–663.

    PubMed  CAS  Google Scholar 

  99. Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994; 35: 1944–1950.

    PubMed  CAS  Google Scholar 

  100. Lin J-D, Kao P-F, Chao T-C. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 1998; 71: 307–313.

    PubMed  CAS  Google Scholar 

  101. DiRusso G, Kern KA. Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer. Surgery (St. Louis) 1994; 116: 1024–1030.

    CAS  Google Scholar 

  102. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995; 36: 21–27.

    PubMed  CAS  Google Scholar 

  103. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35: 1418–1422.

    PubMed  CAS  Google Scholar 

  104. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18: 600–604.

    PubMed  CAS  Google Scholar 

  105. McHenry C, Jarosz H, Davis M, Barbato AL, Lawrence AM, Paloyan E. Selective postoperative radioactive iodine treatment of thyroid carcinoma. Surgery (St. Louis) 1989; 106: 956–959.

    CAS  Google Scholar 

  106. Morris DM, Boyle PJ, Stidley CA, Altobelli KK, Parnell T, Key C. Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and l31í therapy. Ann Surg Oncol 1998; 5: 329–337.

    PubMed  CAS  Google Scholar 

  107. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188–196.

    PubMed  CAS  Google Scholar 

  108. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888–896.

    PubMed  CAS  Google Scholar 

  109. Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis. Ann Surg 1988;227:533–541.

    PubMed  CAS  Google Scholar 

  110. Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170: 467–470.

    PubMed  CAS  Google Scholar 

  111. Melliere DJM, Yahia NEB, Becquemin JP, Lange F, Boulandour H. Thyroid carcinoma with tracheal or esophageal involvement: limited or maximal surgery? Surgery (St. Louis) 1993, 113: 166–172.

    CAS  Google Scholar 

  112. Ozaki O, Sugino K, Mimura T, Ito K. Surgery for patients with thyroid carcinoma invading the trachea: circumferential sleeve resection followed by end-to-end anastomosis. Surgery (St. Louis) 1995; 117: 268–271.

    CAS  Google Scholar 

  113. Ballantyne AJ. Resections of the upper aerodigestive tract for locally invasive thyroid cancer. Am J Surg 1994; 168: 636–639.

    PubMed  CAS  Google Scholar 

  114. Scheumann GFW, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World j Surg 1994; 18: 559–568.

    PubMed  CAS  Google Scholar 

  115. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995; 80: 2946–2953.

    PubMed  CAS  Google Scholar 

  116. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297–305.

    PubMed  CAS  Google Scholar 

  117. Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991; 66: 11–22.

    PubMed  CAS  Google Scholar 

  118. Grant CS. Operative and postoperative management of the pa tient with follicular and Hurthle cell carcinoma. Surg Clin North Am 1995; 75: 395–403

    PubMed  CAS  Google Scholar 

  119. Terry JH, St. John SA, Karkowski FJ, et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 1994; 168: 59–461.

    Google Scholar 

  120. Moreno-Egca A, Rodriguez-Gonzalez JM, Sola-Perez J, Soria Cogollos T, Parrilla-Paricio P. Multivariate analysis of histo pathological features as prognostic factors in patients with pap illary thyroid carcinoma. Br J Surg 1995; 82: 1092–1094.

    Google Scholar 

  121. Segal K, Fridental R, Lubin E, Shvero J, Sulkes J, Feinmesser R.Papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1995; 113: 356–363.

    PubMed  CAS  Google Scholar 

  122. Ruiz de Almodovar JM, Ruiz-Garcia J, Olea N, Villalobos M, Pe- Spreafico G, draza V. Analysis of risk of death from differentiated thyroid cancer. Radiother Oncol 1994; 31: 207–212.

    Google Scholar 

  123. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery (St. Louis) 1987; 102: 1088–1095

    CAS  Google Scholar 

  124. Hay ID, Grant CS, Taylor WF, McConahey WM. Thyroid gland. In Beahrs OH, Myers MH, eds. Manual for Staging of Cancer. Philadelphia: Lippincott. 1988: 55–60.

    Google Scholar 

  125. Noguchi S, Murakami N, Kawamoto H. Classification of papil lary cancer of the thyroid based on prognosis. World J Surg 1994; 18: 552–558.

    PubMed  CAS  Google Scholar 

  126. Ladenson PW. Optimal laboratory testing for diagnosis and mon itoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem 1996; 42: 183–187.

    PubMed  CAS  Google Scholar 

  127. Ozata M, Suzuki S, Takahide M, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98–105.

    PubMed  CAS  Google Scholar 

  128. Coburn M, Teates D, Wanebo H. Recurrent thyroid cancer. Ann Surg 1994; 291: 587–595.

    Google Scholar 

  129. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer: impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer (Phila)1996; 77: 172–180.

    Google Scholar 

  130. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospo darowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of pa tients with differentiated thyroid carcinoma. Cancer (Phila) 1998; 82: 375–388.

    Google Scholar 

  131. Moley JF. Medullary thyroid cancer. Surg Clin North Am 1995; 75: 405–420.

    PubMed  CAS  Google Scholar 

  132. Wells SA, Chi DD, Toshima K, et al. Predictive DNA Testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 220: 237–250.

    PubMed  Google Scholar 

  133. Howe JR, Norton JA, Wells SA. Prevalence of pheochromocy toma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery (St. Louis) 1993; 114: 1070–1077.

    CAS  Google Scholar 

  134. Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herfarth C. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery (St. Louis) 1993; 114: 491–496.

    CAS  Google Scholar 

  135. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and rognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6: 305–310.

    PubMed  CAS  Google Scholar 

  136. Dottorini ME, Assi A, Sironi M, Sangalli G, Colombo L. Multivarate analysis of patients with medullary thyroid carcinoma. Cancer (Phila) 1996; 77: 1556–1565.

    CAS  Google Scholar 

  137. Hoie J, Jorgensen OG, Stenwig AE, Langmark F. Medullary thy-roid cancer in Norway. Acta Chir Scand 1988; 154: 339–343.

    Google Scholar 

  138. Baudin E, Lumbroso J, Schlumberg M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912–916.

    PubMed  CAS  Google Scholar 

  139. Dorr U, Sautter-Bihl M-L, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 1994; 21: 42–45.

    PubMed  CAS  Google Scholar 

  140. Juweid M, Sharkey RM, Swayne LC, Goldenberg DM. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery (St. Louis) 1997; 122: 1156–1165.

    CAS  Google Scholar 

  141. Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998; 227: 887–895.

    PubMed  CAS  Google Scholar 

  142. Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA. Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 1998; 243: 521–526.

    PubMed  CAS  Google Scholar 

  143. Tung WS, Vesely TM, Moley JF. Laparoscopie detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery (St. Louis) 1995; 118: 1024–1030.

    CAS  Google Scholar 

  144. Tan RK, Robert K, Finley I, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995; 17: 41–48.

    PubMed  CAS  Google Scholar 

  145. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy,and surgery in anaplastic thyroid carcinoma. Cancer (Phila) 1994; 74: 1348–1354.

    CAS  Google Scholar 

Download references

Authors
  1. Ronald J. Weigel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  2. Surgical Service, San Francisco VA Medical Center, San Francisco, California, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  3. Division of General Surgery, Duke University Medical Center, Durham, North Carolina, USA

    R. Randal Bollinger MD, PhD (Professor of Surgery, Professor of Immunology, Chief) (Professor of Surgery, Professor of Immunology, Chief)

  4. Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    Alfred E. Chang MD (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  5. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Stephen F. Lowry MD (Professor and Chairman) (Professor and Chairman)

  6. Division of General Surgery, University of California, San Francisco, San Francisco, California, USA

    Sean J. Mulvihill MD (Professor of Surgery, Chief) (Professor of Surgery, Chief)

  7. Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, Michigan, USA

    Harvey I. Pass MD (Professor of Surgery and Oncology, Chief of Thoracic Oncology) (Professor of Surgery and Oncology, Chief of Thoracic Oncology)

  8. Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

    Robert W. Thompson MD (Associate Professor of Surgery) (Associate Professor of Surgery)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Weigel, R.J. (2001). Thyroid. In: Norton, J.A., et al. Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57282-1_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57282-1_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63239-6

  • Online ISBN: 978-3-642-57282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation